S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Are Gene Therapy Stocks The Market's Next Big Winners?
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
This Stock Could Go Up 66% or More. (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Are Gene Therapy Stocks The Market's Next Big Winners?
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
This Stock Could Go Up 66% or More. (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Are Gene Therapy Stocks The Market's Next Big Winners?
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
This Stock Could Go Up 66% or More. (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Are Gene Therapy Stocks The Market's Next Big Winners?
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
This Stock Could Go Up 66% or More. (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Stock Forecast, Price & News

$11.98
+0.46 (+3.99%)
(As of 09/25/2023 ET)
Compare
Today's Range
$11.47
$12.20
50-Day Range
$11.42
$13.98
52-Week Range
$4.82
$14.92
Volume
143,496 shs
Average Volume
161,101 shs
Market Capitalization
$589.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

Alpine Immune Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
50.3% Upside
$18.00 Price Target
Short Interest
Bearish
5.12% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.18) to ($1.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

Medical Sector

868th out of 961 stocks

Pharmaceutical Preparations Industry

410th out of 451 stocks


ALPN stock logo

About Alpine Immune Sciences (NASDAQ:ALPN) Stock

Alpine Immune Sciences, Inc., a clinical-stage company, focuses on immune therapeutics. The company has strategic collaborations immunotherapies via protein engineering technologies with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept (ALPN-303), which is in a phase 1b, open-label study of povetacicept in autoimmune cytopenias, including immune thrombocytopenia, warm autoimmune hemolytic anemia, and cold agglutinin disease; and in phase 1b/2a, open-label study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, lupus nephritis, and primary membranous nephropathy. The company is also developing Acazicolcept (ALPN-101), which is in a phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

ALPN Price History

ALPN Stock News Headlines

Alpine Immune Sciences (NASDAQ:ALPN) Sees Large Volume Increase
1907, 1929, 1998, 2007--and now 2023?
Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.
H.C. Wainwright Keeps Their Buy Rating on Alpine Immune Sciences (ALPN)
Analyst Expectations for Alpine Immune Sciences's Future
1907, 1929, 1998, 2007--and now 2023?
Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.
Alpine Immune Sciences (NASDAQ: ALPN)
See More Headlines
Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALPN Company Calendar

Last Earnings
8/14/2023
Today
9/26/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALPN
Employees
126
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.00
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+50.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-57,760,000.00
Net Margins
-201.07%
Pretax Margin
-199.19%

Debt

Sales & Book Value

Annual Sales
$30.06 million
Book Value
$3.90 per share

Miscellaneous

Free Float
28,390,000
Market Cap
$589.42 million
Optionable
Not Optionable
Beta
1.27
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Mitchell H. Gold M.D. (Age 55)
    Exec. Chairman & CEO
    Comp: $778.2k
  • Dr. Stanford Peng M.D. (Age 52)
    Ph.D., Pres and Head of R&D
    Comp: $751.2k
  • Mr. Paul Rickey (Age 44)
    Sr. VP, CFO, Treasurer & Sec.
    Comp: $577.1k
  • Dr. Wayne R. Gombotz (Age 64)
    Chief Technology Officer
  • Temre Johnson
    Head of IR & Corp. Communications
  • Dr. Remy Durand Ph.D. (Age 38)
    Chief Bus. Officer
  • Dr. Andrew Seth Sandler M.D. (Age 58)
    Chief Medical Officer













ALPN Stock - Frequently Asked Questions

Should I buy or sell Alpine Immune Sciences stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALPN shares.
View ALPN analyst ratings
or view top-rated stocks.

What is Alpine Immune Sciences' stock price forecast for 2023?

5 Wall Street analysts have issued 1-year target prices for Alpine Immune Sciences' stock. Their ALPN share price forecasts range from $15.00 to $22.00. On average, they predict the company's share price to reach $18.00 in the next year. This suggests a possible upside of 50.3% from the stock's current price.
View analysts price targets for ALPN
or view top-rated stocks among Wall Street analysts.

How have ALPN shares performed in 2023?

Alpine Immune Sciences' stock was trading at $7.35 at the start of the year. Since then, ALPN stock has increased by 63.0% and is now trading at $11.98.
View the best growth stocks for 2023 here
.

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 2,520,000 shares, an increase of 28.6% from the August 15th total of 1,960,000 shares. Based on an average daily volume of 232,900 shares, the days-to-cover ratio is presently 10.8 days.
View Alpine Immune Sciences' Short Interest
.

When is Alpine Immune Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ALPN earnings forecast
.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) released its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.11. The biotechnology company had revenue of $8.59 million for the quarter, compared to analyst estimates of $8.08 million. Alpine Immune Sciences had a negative trailing twelve-month return on equity of 33.44% and a negative net margin of 201.07%.

What ETF holds Alpine Immune Sciences' stock ?

AdvisorShares Dorsey Wright Micro-Cap ETF holds 2,351 shares of ALPN stock, representing 0.65% of its portfolio.

What other stocks do shareholders of Alpine Immune Sciences own?
What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.78%), Great Point Partners LLC (7.01%), BlackRock Inc. (4.76%), Geode Capital Management LLC (1.29%), State Street Corp (1.19%) and Renaissance Technologies LLC (0.67%). Insiders that own company stock include Decheng Capital China Life Sci, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Robert E Conway and Robert E Conway.
View institutional ownership trends
.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $11.98.

How much money does Alpine Immune Sciences make?

Alpine Immune Sciences (NASDAQ:ALPN) has a market capitalization of $589.42 million and generates $30.06 million in revenue each year. The biotechnology company earns $-57,760,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

How many employees does Alpine Immune Sciences have?

The company employs 126 workers across the globe.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The official website for the company is www.alpineimmunesciences.com. The biotechnology company can be reached via phone at (206) 788-4545, via email at laurence@gilmartinir.com, or via fax at 303-440-8399.

This page (NASDAQ:ALPN) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -